NNC2215, a glucose-sensitive insulin, offers improved glycemic control by dynamically adjusting to blood sugar levels, ...

An insulin that switches itself on and off in response to blood glucose levels has proven successful in lowering the risk of ...

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to ...

Once-weekly insulin vs once-weekly tirzepatide demonstrated superior safety profiles but inferior weight loss and glycemic control outcomes.

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application ...

Continuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening ...

The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism ...

The rejection is related to the timing of the FDA’s reinspection of Zealand’s third-party manufacturer, which previously had ...

Zealand Pharma A/S (ZEAL) said that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL for Part 1 of ...

No. 48 / 2024Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinismU.S. Food and ...

Zealand Pharma said it has received a complete response letter from the Food and Drug Administration related to its new drug application for dasiglucagon for the prevention and treatment of ...